InvestorsHub Logo
Followers 42
Posts 5093
Boards Moderated 0
Alias Born 05/10/2012

Re: tdeck post# 486

Friday, 11/30/2018 3:17:00 PM

Friday, November 30, 2018 3:17:00 PM

Post# of 7492
I think the most likely buyer has always been Novartis. Their IP portfolio for regenerative medicine is lacking and Mike Perry obviously is the common link having held multiple senior titles there and overlapping his time between Avita and Novartis.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RCEL News